Conradi Hünermann Syndrome

Conradi Hünermann Syndrome

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Conradi Hünermann Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • CDPXD2
  • chondrodysplasia punctata, X-linked dominant
  • Conradi-Hunermann-Happle syndrome
  • Happle syndrome

Disorder Subdivisions

  • None

General Discussion

Conradi-Hünermann syndrome is a rare genetic disorder characterized by skeletal malformations, skin abnormalities, cataracts and short stature. The specific symptoms and severity of the disorder may vary greatly from one individual to another. Conradi-Hünermann syndrome is classified as a form of chondrodysplasia punctata, a group of disorders characterized by the formation of small, hardened spots of calcium on the "growing portion" or heads of the long bones (stippled epiphyses) or inside other areas of cartilage in the body. Conradi-Hünermann syndrome is commonly associated with disproportionate and assymetric shortening of long bones, particularly those of the upper arms (humeri) and the thigh bones (femora), curvature of the spine and mild to moderate growth deficiency, resulting in short stature. Many affected individuals also have a prominent forehead; unusually flattened midfacial regions (midfacial hypoplasia), with a low nasal bridge; loss of transparency of the lenses of the eyes (cataracts); sparse, coarse scalp hair; and/or abnormal thickening, dryness, and scaling of the skin. Conradi-Hünermann syndrome is inherited as an X-linked dominant trait that occurs almost exclusively in females.

Symptoms

The symptoms, progression and severity of Conradi-Hünermann syndrome can vary dramatically, even among members of the same family. The disorder can cause serious complications at birth or be so mild that individuals may not be identified until adulthood (usually after having an affected child). It is important to note that affected individuals may not have all of the symptoms discussed below. Affected individuals should talk to their physician and medical team about their specific case, associated symptoms and overall prognosis. The classic symptoms of Conradi-Hünermann syndrome involved the skeleton, skin and eyes. Intelligence is usually unaffected.



Affected infants may fail to grow and gain weight at the rate expected for age and gender (failure to thrive). Growth deficiencies may ultimately result in a final adult height that is below normal (short stature). Some affected infants are prone to developing repeated infections.



During infancy, individuals with Conradi-Hünermann syndrome have small, hardened spots of calcium on the "growing portion" or heads of the long bones (stippled epiphyses) as well as other areas of the cartilaginous skeleton. Cartilage is a tough, elastic type of connective tissue that provides cushion and structure within the body. When the skeleton begins to develop, it predominately consists of cartilage, which is gradually replaced by bone. The development of these abnormal calcified spots may also be known as chondrodysplasia punctata. In infants with Conradi-Hünermann syndrome, punctate calcifications may develop throughout the spinal column, the pelvis, the front ends of the ribs (costal cartilages), the breastbone, the shoulder blades, the collarbones, and, in rare cases, the larynx. Chondrodysplasia punctata tends to resolve on its own within the first few years of life.



Individuals with Conradi-Hünermann syndrome typically have additional musculoskeletal abnormalities. Such features commonly include asymmetric shortening of long bones of the limbs, particularly those of the upper arms (humeri) and the thigh bones (femora), causing disproportionate length of the arms and legs with one side typically more affected than the other. Affected individuals also frequently have abnormal sideways and, in some cases, front-to-back curvature of the spine (scoliosis or kyphoscoliosis). Abnormal stiffness of the joints or joints that are fixed or locked in a bent position (flexion contractures) may also occur. In some cases, additional musculoskeletal abnormalities have also been reported including malformation of the hips (hip dysplasia), webbing of the fingers (syndactyly) and/or extra fingers (polydactyly), defects of the spinal column, and deformities in which the feet are abnormally twisted out of shape or position (clubbed feet).



Some individuals with Conradi-Hünermann syndrome may have clouding of the lenses of the eye (cataracts). Cataracts may be present at birth (congenital) or may develop during infancy. Cataracts may affect one or both eyes. Cataracts can caused blurred vision or decreased clarity of vision. In rare cases, additional eye (ocular) abnormalities include abnormally small eyes (microphthalmos), abnormally small corneas (microcornea), down-slanting eyelid folds (palpebral fissures), rapid, involuntary eye movements (nystagmus), and degeneration of the main nerve that transmits nerve impulses from the retina to the brain (optic atrophy). In some cases, eye abnormalities can significantly reduce vision.



Additional distinctive facial features may occur in some cases including an unusually prominent forehead (frontal bossing), flattened cheekbones (malar hypoplasia), a flattened bridge of the nose, upturned nostrils (anteverted nares) and malformed (dysplastic) ears. Hearing loss has been reported in some cases.



In the newborn period, many affected infants also have redness (erythema) and unusual thickening, dryness, and scaling of the skin (ichthyosiform erythroderma) distributed in a linear, blotchy pattern over the body. Although the eruption usually resolves during infancy, older children may subsequently develop inflammation and wasting (atrophy) of follicles (follicular atrophoderma), causing pores to appear unusually large. In some cases, affected areas of the skin may be darker or lighter than surrounding areas (hyper- and hypopigmentation). Patchy areas of hair loss and scarring may develop on the scalp (cicatricial alopecia). The sparse scalp hair may also be unusually coarse and lusterless.



In some instances, additional abnormalities have also been reported in association with Conradi-Hünermann syndrome. Such features have included abnormal calcifications and potential narrowing (stenosis) of the windpipe (trachea) and/or the larynx, which connects the throat and the trachea; an unusually short neck; abnormalities of the nails; various structural malformations of the heart (congenital heart defects); and/or other physical findings.

Causes

Conradi-Hünermann syndrome is caused by mutations of the emopamil-binding protein (EBP) gene. In many cases, this mutation occurs randomly, for no apparent reason (i.e., new mutation). The gene mutation is inherited as an X-linked dominant trait. Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.



X-linked dominant disorders are conditions caused by an abnormal gene on the X chromosome. Females have two X chromosomes, whereas males have one X chromosome and one Y chromosome. In females, certain disease traits on the X chromosome may in some cases be "masked" by the normal gene on the other X chromosome (random X-chromosome inactivation). However, since males have only one X chromosome, if they inherit a gene for a disease present on the X, it is more likely to be fully expressed. According to researchers, in males who inherit a disease gene for an X-linked dominant disorder (hemizygotes), it is suspected that full expression of the disorder may be associated with loss of life before birth. In rare cases, males have been reported with Conradi-Hünermann syndrome, most likely as a postzygotic mutation (acquired during embryonic life and not inherited from the parents) or in individuals with an abnormal XXY chromosomal makeup. Men with a disease gene for an X-linked disorder transmit the gene to their daughters but not to their sons. Women with a copy of the disease gene have a 50 percent risk of transmitting the gene to their daughters and their sons.



Investigators have determined that the EBP gene is located on the short arm (p) of the X chromosome (Xp11.23-p11.22). Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Human body cells normally have 46 chromosomes. Pairs of human chromosomes are numbered from 1 through 22 and the sex chromosomes are designated X and Y. Males have one X and one Y chromosome and females have two X chromosomes. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome Xp11.23-p11.22" refers to bands 11.23-11.22 on the short arm of the X chromosome. The numbered bands specify the location of the thousands of genes that are present on each chromosome.



The EBP gene creates a protein known as emopamil-binding protein. Mutations of the EBP gene result in deficient levels of functional copies of this protein. Emopamil-binding protein functions as a sterol-8-isomerase enzyme and plays a role in cholesterol biosynthesis. Biosynthesis is the building or conversion of complex chemical compounds from simple substances in the body. The clinical picture of Conradi-Hünermann syndrome is thought to be related to the accumulation of cholesterol precursor compounds (sterols) that are toxic.



In some cases of Conradi-Hünermann syndrome, where there is no apparent family history, the disorder may occur due to gonadal mosaicism. Such cases include rare instances in which more than one child of apparently unaffected parents have the disorder. In gonadal mosaicism, some of a parent's reproductive cells (germ cells) may carry the gene mutation while others contain a normal cell line ("mosaicism"). As a result, one or more of the parent's children may inherit the gene mutation, potentially leading to manifestation of the disorder, while the parent may have no apparent symptoms (asymptomatic carrier). Gonadal mosaicism may be suspected when apparently unaffected parents have more than one child with the same genetic abnormality. Within families, there is variation in the severity of the clinical picture between affected females, and this is largely secondary to differences in X-inactivation.

Affected Populations

Conradi-Hünermann syndrome is a rare disorder that almost exclusively affects women. The exact incidence of the disorder in the general population is unknown, although one estimate places it at 1 in 100,000 individuals. The disorder is often apparent at birth (congenital), but some individuals with mild cases may not be indentified until adulthood.



Chondrodysplasia punctata was first described in the medical literature by Drs. Conradi and Hünermann in 1931. Although the term Conradi-Hünermann was once used to described chondrodysplasia punctata in general, the term names is specifically used to denote X-linked dominant chondrodysplasia punctata, which as fully described in the medical literature by Happle in 1970s.

Standard Therapies

Diagnosis

A diagnosis of Conradi-Hünermann syndrome is made based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. X-ray (radiographic), eye (ophthalmologic), skin (dermatological), and biochemical examinations may all be performed to help make a diagnosis of Conradi-Hünermann syndrome. X-ray evaluation may reveal characteristic stippling of epiphyses and other regions of the cartilaginous skeleton. However, as noted above, there is loss of distinctive epiphyseal stippling over time, potentially making diagnosis difficult. In addition, there have been instances in which individuals with only mild manifestations have not been identified until adulthood.



An important test to confirm a diagnosis of Conradi-Hünermann syndrome is evaluating the plasma for elevated levels of a substance known as sterols. Mutations of the EBP gene result in the accumulation of sterols in the plasma and certain tissues of the body. Sterol levels are measured by gas chromatography-mass spectrometry.



A diagnosis of Conradi-Hünermann syndrome can be confirmed through molecular genetic testing, which can identify the characteristic genetic mutation that causes the disorder.



Treatment

The treatment of Conradi-Hünermann syndrome is directed toward the specific symptoms that are apparent in each individual. Such treatment may require the coordinated efforts of a team of medical professionals, such as pediatricians; physicians who diagnose and treat disorders of the skeleton, joints, muscles, and related tissues (orthopedists); skin specialists (dermatologists); eye specialists; and/or other health care professionals.



Various orthopedic measures, including surgery, may be recommended to help prevent, treat, or correct certain skeletal abnormalities associated with the disorder. Surgery may also be advised for certain craniofacial malformations, scoliosis or other physical abnormalities. The surgical procedures performed will depend on the nature, severity, and combination of anatomical abnormalities, their associated symptoms, and other factors.



Recommended treatment for congenital cataracts may include early surgical removal of the cataracts (when they interfere with vision); implantation of artificial lenses in some cases; and/or certain measures following surgery, such as the use of corrective lenses, to help achieve good vision.



For those affected by ichthyosis and skin abnormalities, supportive measures may be recommended, such as bathing with bath oil and/or applying appropriate skin ointments and lubricants that soften and soothe the skin (emollients).



Genetic counseling may be of benefit for affected individuals and their families. Other treatment is symptomatic and supportive.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com



Contact for additional information about Conradi-Hünermann syndrome:



Nancy Braverman, MS, MD

Associate Professor

McGill University and the Montreal Children's Hospital Research Institute

4060 St Catherine West, Montreal

QC, Canada, H3Z 2Z3

phone: 514-934-1934, ext. 23404

FAX : 514-412-4478

email: nancy.braverman@mcgill.ca

References

TEXTBOOKS

Jones KL. Ed. Smith's Recognizable Patterns of Human Malformation. 6th ed. Elsevier Saunders, Philadelphia, PA; 2006:437.



James WD, Berger TG, Elston DM. Eds. Andrew's Diseases of the Skin: Clinical Dermatology. 10th ed. Saunders. 2005:549.



Braverman N. Conradi-Hünermann Syndrome. NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:173.



Rimoin D, Connor JM, Pyeritz RP, Korf BR. Eds. Emory and Rimoin's Principles and Practice of Medical Genetics. 4th ed. Churchill Livingstone. New York, NY; 2002:380-3801.



Spranger JW, Brill PW, Poznanski AK, eds. Bone Dysplasias: An Atlas of Genetic Disorders and Skeletal Development., 2nd ed. Oxford University Press, New York, NY;2002:66.



Gorlin RJ, Cohen MMJr, Hennekam RCM. Eds. Syndromes of the Head and Neck. 4th ed. Oxford University Press, New York, NY; 2001:222-224.



JOURNAL ARTICLES

Kolb-Mauer A, Grzeschik KH, Haas D, Brocker EB, Hamm H. Conradi-Hünermann syndrome-Happle syndrome (X-linked dominant chondrodysplasia punctata) confirmed by plasma sterol and mutation analysis. Acta Derm Venereol. 2008;88:47-51.



Offiah AC, Mansour S, Jeffrey I, et al. Greenberg dysplasia (HEM) and lethal X linked dominant Conradi-Hünermann chondrodysplasia punctata (CDPX2): presentation of two cases with overlapping phenotype. J Med Genet. 2003;40:e129.



Aughton DJ, Kelley RI, Metzenberg A, et al. X-linked dominant chondrodysplasia punctata (CDPX2) caused by single gene mosaicism in a male. Am J Med Genet. 2003;116A:255-260.



Has C, Seedorf U, Kannenberg F, et al. Gas chromatography-mass spectrometry and molecular genetic studies in families with the Conradi-Hünermann-Happle syndrome. J Invest Dermatol. 2002;118:851-858.



Has C, Bruckner-Tuderman L, et al. The Conradi-Hünermann-Happle syndrome (CDPX2) and emopamil binding protein: novel mutations, and somatic and gonadal mosaicism. Hum Mol Genet. 2000;9:1951-1955.



Braverman N, Lin P, Moebius FF, et al. Mutations in the gene encoding 3ß-hydroxysteroid-?8,?7-isomerase cause X-linked dominant Conradi-Hünermann syndrome. Nat Genet. 1999;22:291-294.



FROM THE INTERNET

Whittock NV, Izatt L. X-linked Dominant Chondrodysplasia Punctata. Orphanet encyclopedia, July 2004. Available at: http://www.orpha.net/data/patho/GB/uk-CDPX2.pdf Accessed on: July 8, 2010.



McKusick VA., ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No:302960; Last Update:04/09/2009. Available at: http://www.ncbi.nlm.nih.gov/omim/302960 Accessed on: July 8, 2010.

Resources

Human Growth Foundation

997 Glen Cove Avenue

Suite 5

Glen Head, NY 11545

Tel: (516)671-4041

Fax: (516)671-4055

Tel: (800)451-6434

Email: hgf1@hgfound.org

Internet: http://www.hgfound.org/



MAGIC Foundation

6645 W. North Avenue

Oak Park, IL 60302

Tel: (708)383-0808

Fax: (708)383-0899

Tel: (800)362-4423

Email: mary@magicfoundation.org

Internet: http://www.magicfoundation.org



Foundation for Ichthyosis & Related Skin Types

2616 N Broad Street

Colmar, PA 18915

Tel: (215)997-9400

Fax: (215)997-9403

Tel: (800)545-3286

Email: info@firstskinfoundation.org

Internet: http://www.firstskinfoundation.org



Little People of America, Inc.

250 El Camino Real Suite 201

Tustin, CA 92780

Tel: (714)368-3689

Fax: (714)368-3367

Tel: (888)572-2001

Email: info@lpaonline.org

Internet: http://www.lpaonline.org/



Restricted Growth Association

PO Box 5137

Yeovil, BA20 9FF

United Kingdom

Tel: 03001111970

Fax: 03001112454

Email: office@restrictedgrowth.co.uk

Internet: http://www.restrictedgrowth.co.uk



NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases

Information Clearinghouse

One AMS Circle

Bethesda, MD 20892-3675

USA

Tel: (301)495-4484

Fax: (301)718-6366

Tel: (877)226-4267

TDD: (301)565-2966

Email: NIAMSinfo@mail.nih.gov

Internet: http://www.niams.nih.gov/



NIH/National Eye Institute

31 Center Dr

MSC 2510

Bethesda, MD 20892-2510

United States

Tel: (301)496-5248

Fax: (301)402-1065

Email: 2020@nei.nih.gov

Internet: http://www.nei.nih.gov/



Coalition for Heritable Disorders of Connective Tissue (CHDCT)

4301 Connecticut Avenue, NW Suite 404

Washington, DC 20008

Tel: (202)362-9599

Fax: (202)966-8553

Tel: (800)778-7171

Email: chdct@pxe.org

Internet: http://www.chdct2.org/



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.